Howland Capital Management LLC Sells 5,314 Shares of Astrazeneca PLC (AZN)
Howland Capital Management LLC decreased its position in Astrazeneca PLC (NYSE:AZN) by 8.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 57,686 shares of the company’s stock after selling 5,314 shares during the period. Howland Capital Management LLC’s holdings in Astrazeneca PLC were worth $1,896,000 as of its most recent filing with the SEC.
Other large investors have also recently bought and sold shares of the company. Fisher Asset Management LLC raised its position in shares of Astrazeneca PLC by 45.2% in the second quarter. Fisher Asset Management LLC now owns 338,979 shares of the company’s stock worth $10,159,000 after buying an additional 105,570 shares in the last quarter. Fruth Investment Management raised its stake in Astrazeneca PLC by 3.4% in the second quarter. Fruth Investment Management now owns 7,649 shares of the company’s stock worth $230,000 after buying an additional 249 shares during the period. Creative Planning raised its stake in Astrazeneca PLC by 114.5% in the second quarter. Creative Planning now owns 28,228 shares of the company’s stock worth $852,000 after buying an additional 15,069 shares during the period. NEXT Financial Group Inc raised its stake in Astrazeneca PLC by 8.8% in the second quarter. NEXT Financial Group Inc now owns 6,305 shares of the company’s stock worth $190,000 after buying an additional 509 shares during the period. Finally, New England Research & Management Inc. acquired a new stake in Astrazeneca PLC during the second quarter worth about $777,000. 13.05% of the stock is owned by institutional investors.
Shares of Astrazeneca PLC (NYSE:AZN) traded down 0.07% during midday trading on Tuesday, hitting $26.71. The company had a trading volume of 6,372,927 shares. Astrazeneca PLC has a one year low of $25.88 and a one year high of $35.04. The stock has a market capitalization of $67.58 billion, a price-to-earnings ratio of 27.41 and a beta of 0.83. The stock’s 50-day moving average price is $28.71 and its 200-day moving average price is $30.78.
Astrazeneca PLC (NYSE:AZN) last issued its earnings results on Thursday, November 10th. The company reported $1.32 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.74 by $0.58. The firm had revenue of $5.70 billion for the quarter, compared to the consensus estimate of $5.95 billion. Astrazeneca PLC had a return on equity of 31.30% and a net margin of 10.35%. The company’s revenue was down 2.6% compared to the same quarter last year. During the same quarter last year, the business posted $1.03 EPS. Analysts predict that Astrazeneca PLC will post $3.02 EPS for the current year.
WARNING: “Howland Capital Management LLC Sells 5,314 Shares of Astrazeneca PLC (AZN)” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The correct version of this story can be accessed at https://www.thecerbatgem.com/2016/11/29/howland-capital-management-llc-sells-5314-shares-of-astrazeneca-plc-azn.html.
A number of research firms have issued reports on AZN. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Astrazeneca PLC in a report on Monday, August 8th. Deutsche Bank AG reaffirmed a “buy” rating on shares of Astrazeneca PLC in a report on Monday, October 10th. Citigroup Inc. reaffirmed a “buy” rating on shares of Astrazeneca PLC in a report on Monday, November 7th. Bank of America Corp. set a $41.00 price objective on Astrazeneca PLC and gave the stock a “buy” rating in a report on Tuesday, October 4th. Finally, Beaufort Securities reissued a “hold” rating on shares of Astrazeneca PLC in a report on Friday, November 11th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Astrazeneca PLC has a consensus rating of “Buy” and an average price target of $37.61.
Astrazeneca PLC Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Stock Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related stocks with our FREE daily email newsletter.